CushieBlog

Corcept markets Korlym® for the treatment of Cushing’s syndrome, a severe orphan illness that afflicts 20,000 people in the United States, approximately half of whom are cured by surgery. Corcept believes that revenue from the sale of Korlym, combined with the company’s cash reserves, will allow it to reach cash flow breakeven while fully supporting its development activities.

via Warrant Exercises Generate $17.2 Million; Proceeds to Advance Next-Generation Compounds and Support Commercialization of Korlym(R).

Filed under: Cushing's, Treatments | Tagged: Corcept, Cushing's Syndrome, Korlym, surgery |